HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SRRK
Scholar Rock Holding Corporation
There isn't enough reported data to score SRRK yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SRRK Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Weak | |
| Unavailable |
SRRK's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SRRK PE Valuation
SRRK has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SRRK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect SRRK's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over SRRK on earnings, with more consistent year-over-year improvement.
SRRK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.22 | -$0.05 |
| Q2 2026 | -$3.31 | -$0.38 |
| Q1 2026 | -$3.45 | -$0.90 |
| Q4 2025 | -$3.29 | -$0.82 |
| Q3 2025 | -$3.17 | -$0.82 |
| Q2 2025 | -$2.93 | -$0.71 |
| Q1 2025 | -$2.55 | -$0.46 |
| Q4 2024 | -$2.47 | -$0.48 |
SRRK lost $3.22 per share over the past year, about the same as its loss the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SRRK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over SRRK on profitability, with a higher operating margin.
SRRK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2022 | $33.2M | +605% |
| Q4 2021 | $4M | +18% |
| Q3 2021 | $5.5M | +80% |
| Q2 2021 | $4.6M | +18% |
| Q1 2021 | $4.7M | -6.4% |
| Q4 2020 | $3.4M | -55% |
SRRK's revenue is growing: $570,000 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -18607% | N/A |
| Q1 2022 | -21% | +557 points |
| Q4 2021 | -873% | -114 points |
| Q3 2021 | -679% | +99 points |
| Q2 2021 | -659% | -160 points |
| Q1 2021 | -578% | -226 points |
| Q4 2020 | -760% | -597 points |
| Q3 2020 | -778% | N/A |
SRRK's operating margin was −18607% last quarter, down 17948 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SRRK on cash generation, producing positive trailing cash flow while its opponent burns cash.
SRRK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$81.9M | -$12.9M |
| Q2 2026 | -$70.3M | +$6.8M |
| Q1 2026 | -$82.2M | -$3.2M |
| Q4 2025 | -$75.5M | -$26M |
| Q3 2025 | -$69M | -$16.5M |
| Q2 2025 | -$77.2M | -$27.9M |
| Q1 2025 | -$78.9M | -$29.1M |
| Q4 2024 | -$49.5M | -$12.2M |
SRRK has burned cash in almost every quarter: −$310M over the past year, against −$275M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SRRK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SRRK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +1.8M shares |
| 1 year | +16% | +18.6M shares |
| 3 years | +64% | +51.8M shares |
| 5 years | +262% | +95.8M shares |
| Available history | +381% | +105M shares |
SRRK has 132M diluted shares, up 16% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SRRK Net Leverage
SRRK's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SRRK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 25.9 | Neutral |
SRRK's weekly RSI is 44 (neutral) and its Stochastic is 26 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SRRK PE vs Healthcare Sector
SRRK has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SRRK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.1 | 2.2% below |
| 20 week MA | $49.5 | 13% below |
| 50 week MA | $47.5 | 9.2% below |
| 100 week MA | $41.5 | 4.1% above |
| 200 week MA | $27.1 | 59% above |
SRRK has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SRRK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.0 | $51.5 | +296% |
| 2021 | $51.5 | $25.4 | -51% |
| 2022 | $25.4 | $7.97 | -69% |
| 2023 | $7.97 | $18.8 | +136% |
| 2024 | $18.8 | $44.5 | +136% |
| 2025 | $44.5 | $45.7 | +2.7% |
| 2026 YTD | $45.7 | $43.2 | -5.5% |
SRRK has the edge over HIMS on returns for 2026, with the stronger performance.